ArticleP & T : a peer-reviewed journal for formulary management2009
Nebivolol (bystolic), a novel Beta blocker for hypertension.
Article in P & T : a peer-reviewed journal for formulary management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study.Scientific reports · 2026Trial
- Pectin nanoparticles loaded with nitric oxide donor drug: A potential approach for tissue regeneration.International journal of pharmaceutics: X · 2024Article
- Comprehensive list of preventative migraine headache medications without significant drug-drug interactions.Frontiers in neurology · 2024Article
- Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.Cardiovascular drugs and therapy · 2022Review
- The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension.Cardiology research and practice · 2022Article
- FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.Nature communications · 2021Article
- RETRACTED: Investigation of the Potential of Nebivolol Hydrochloride-Loaded Chitosomal Systems for Tissue Regeneration: In Vitro Characterization and In Vivo Assessment.Pharmaceutics · 2021Article
- A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.PloS one · 2021Article
- Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation.Polymers · 2019Article
- Hypertension in African Americans.Current cardiology reports · 2017Review
- Pharmacological update: New drugs in cardiac practice: A critical appraisal.Annals of cardiac anaesthesia · 2017Review
- Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers.Clujul medical (1957) · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
19561858PMC2697096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.